Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Blood (2022) 140 (Supplement 1): 1761–1764.

https://doi.org/10.1182/blood-2022-166543

Published: 2022

Journal Articles

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Blood (2022) 140 (Supplement 1): 9802–9803.

https://doi.org/10.1182/blood-2022-167716

Published: 2022

Journal Articles

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Blood (2021) 138 (Supplement 1): 4671.

https://doi.org/10.1182/blood-2021-150322

Published: 2021

Journal Articles

A Phase 1b Study of Eltrombopag and Azacitidine in Patients with High Risk Myelodysplastic Syndromes and Related Disorders

Alex Sternberg, MRCP,FRCPath, Rebecca H. Boucher, BSc, MSc, PhD, Helen C Coulthard, BSc, Manoj Raghavan, MBBS, PhD MRCP, FRCPath, Dominic J. Culligan, MD, Aimee Jackson, BSc, MSc, Catherine Cargo, MB, PhD, Mike Dennis, MD, Marlen Metzner, MSc, Rachel Moore, BA, David Bowen, MD, Paresh Vyas, MRCP, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-134227

Published: 2020

Journal Articles

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Blood (2019) 134 (Supplement_1): 2879.

https://doi.org/10.1182/blood-2019-122830

Published: 2019

Journal Articles

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Blood (2018) 132 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2018-99-118070

Published: 2018

Journal Articles

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study

Steven Knapper, DM, Michael Dennis, MD, MRCP, FRCPath, Mark W Drummond, PhDMD, Robert K. Hills, MA, DPhil, MSc, Richard James Dillon, MA, PhD MRCP, FRCPath, Christopher Pocock, MD PhD, Dominic J. Culligan, Paresh Vyas, Daniel Wiseman, MB, ChB, Joanna Zabkiewicz, PhD, Marie Hodges, PhD MSc, Catherine Cargo, MB, FRCPath, Jan Taylor, PhD MSc, BSc, Laura Upton, Melissa Wright, David Bowen, MD PhD

Blood (2018) 132 (Supplement 1): 1818.

https://doi.org/10.1182/blood-2018-99-110356

Published: 2018

Journal Articles

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Laurie H Sehn, MDMPH, Angela Giovanna Congiu, Dominic J. Culligan, Mercedes Gironella, Dok Hyun Yoon, Michinori Ogura, Andras Rosta, Jun Zhu, Aino Launonen, Tina Nielsen, Gila Sellam, Marek Trněný, Umberto Vitolo, Maurizio Martelli

Blood (2018) 132 (Supplement 1): 783.

https://doi.org/10.1182/blood-2018-99-116845

Published: 2018

Journal Articles

Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

Blood (2018) 132 (Supplement 1): 572.

https://doi.org/10.1182/blood-2018-99-111901

Published: 2018

Journal Articles

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry

Marlijn Hoeks, MD, Saskia Langemeijer, MD PhD, Louise De Swart, MD, Tim Bagguley, Corine van Marrewijk, PhD, David Bowen, MD PhD, Jaroslav Cermak, Eva Hellstrom-Lindberg, MD PhD, Aurelia Tatic, MD, Argiris Symeonidis, Marian G.J. Van Kraaij, MD PhD, Panagiotis Panagiotidis, Hege Garelius, MD, Dominic J Culligan, Marta Krejci, MD PhD, Jackie Droste, PhD, Alexandra Smith, PhD, Dorine W. Swinkels, MD PhD, Theo de Witte, MD PhD

Blood (2016) 128 (22): 4327.

https://doi.org/10.1182/blood.V128.22.4327.4327

Published: 2016

Journal Articles

Exome Sequencing and Linkage Analysis Implicates Two Candidate Genes On Chromosome 3p in Familial Hodgkin Lymphoma

Alastair Lawrie, Timothee Cezard, Dominic J Culligan, Mark A Vickers

Blood (2012) 120 (21): 53.

https://doi.org/10.1182/blood.V120.21.53.53

Published: 2012

Journal Articles

Local and systemic induction of CD4 + CD25 + regulatory T-cell population by non-Hodgkin lymphoma

Sajjan Mittal, Neil A. Marshall, Linda Duncan, Dominic J. Culligan, Robert N. Barker, Mark A. Vickers

Blood (2008) 111 (11): 5359–5370.

https://doi.org/10.1182/blood-2007-08-105395

Published: 2008

Includes: Supplemental data

Journal Articles

Transmission of Chromosomally Integrated HHV6 by Allogeneic Peripheral Blood Stem Cell Transplantation Associated with the Development of a Fatal Macrophage Activation (Haemophagocytic) Syndrome.

Mark Crowther, MD, Pamela Molyneaux, MD, William F. Carman, MD, Kate N. Ward, MD, Dominic J. Culligan, MD

Blood (2006) 108 (11): 5278.

https://doi.org/10.1182/blood.V108.11.5278.5278

Published: 2006

Journal Articles

Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma

Neil A. Marshall, Linsey E. Christie, Laura R. Munro, Dominic J. Culligan, Peter W. Johnston, Robert N. Barker, Mark A. Vickers

Blood (2004) 103 (5): 1755–1762.

https://doi.org/10.1182/blood-2003-07-2594

Published: 2004

NARROW

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

A Phase 1b Study of Eltrombopag and Azacitidine in Patients with High Risk Myelodysplastic Syndromes and Related Disorders

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry

Exome Sequencing and Linkage Analysis Implicates Two Candidate Genes On Chromosome 3p in Familial Hodgkin Lymphoma

Local and systemic induction of CD4 + CD25 + regulatory T-cell population by non-Hodgkin lymphoma

Transmission of Chromosomally Integrated HHV6 by Allogeneic Peripheral Blood Stem Cell Transplantation Associated with the Development of a Fatal Macrophage Activation (Haemophagocytic) Syndrome.

Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only